Perry A Karsen
CIK 1260573 · see remarks · last filed 2023-07-21
Perry A Karsen is a corporate insider who has filed 65 SEC Form 4 insider transactions across 7 companies since 2012. The most recent filing, for GRPH, was dated Jul 21, 2023. Across all open-market trades the lifetime net is −$37.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $306.8K across reported positions. 33 SEC filings were submitted jointly with CELGENE CORP /DE/.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CELGZ price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
86 MORRIS AVENUE
SUMMIT, NJ 07901
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LENZ Therapeutics, Inc. (GRPH) Delisted | Director | 23,433 | $22.26 | $521.6K | $0 | 3 | 2023-07-21 |
| Jounce Therapeutics, Inc. (JNCE) Delisted | Director | 0 | $1.88 | $0 | $80.0K | 8 | 2023-05-04 |
| NTLA | Director | 26,336 | $11.65 | $306.8K | -$4.75M | 7 | 2020-12-18 |
| VYGR | Director | — | $2.02 | — | $0 | 4 | 2019-06-17 |
| CELGENE CORP /DE/ (CELGZ) Delisted | see remarks | 68,071 | — | — | -$32.62M | 30 | 2015-12-18 |
| NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) Delisted | Director | 1,876 | $0.00 | $0 | $0 | 5 | 2015-07-21 |
| AGIO | Director | — | $37.18 | — | $0 | 1 | 2015-06-25 |
Recent Filings
65 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-07-21 | LENZ Therapeutics, Inc. (GRPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-05-04 | Jounce Therapeutics, Inc. (JNCE) Delisted | Mixed | −5,000 | $0 | EDGAR |
| 2022-06-28 | Jounce Therapeutics, Inc. (JNCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-22 | LENZ Therapeutics, Inc. (GRPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-07-01 | LENZ Therapeutics, Inc. (GRPH) Delisted | Mixed | +8,126 | $0 | EDGAR |
| 2021-06-22 | Jounce Therapeutics, Inc. (JNCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-12-18 | NTLA | Mixed | — | -$3.12M | EDGAR |
| 2020-07-02 | Jounce Therapeutics, Inc. (JNCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-29 | Jounce Therapeutics, Inc. (JNCE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-19 | NTLA | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.